A Phase III, 12-week, Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Determine the Efficacy, Safety, and Tolerability of a Dose of 15 mg Bid of Evenamide as add-on in Patients With Documented Treatment-resistant Schizophrenia, Which is Not Adequately Controlled by a Stable Therapeutic Dose of the Patient's Current Antipsychotic Medication(s)

This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in patients with documented treatment-resistant schizophrenia (TRS) who have prospectively demonstrated inadequate response to their current stable therapeutic dose of an antipsychotic(s). Approximately 400 patients will be randomized equally (1:1) to each of the two treatment groups in this study.

Start Date23 Jan 2026

Sponsor / Collaborator

Newron Pharmaceuticals SpA

100 Clinical Results associated with Evenamide Hydrochloride

100 Translational Medicine associated with Evenamide Hydrochloride

100 Patents (Medical) associated with Evenamide Hydrochloride

Literatures (Medical) associated with Evenamide Hydrochloride

01 Apr 2026·EUROPEAN NEUROPSYCHOPHARMACOLOGY

Emerging neurobiological targets in psychiatric treatment

Review

Author: Berk, Michael ; Govinnage, Janani ; Giorlando, Frank ; De Zoysa, Agampodi Ishan ; Narayanaswamy, J C ; Dodd, Seetal

Despite significant advancements in psychopharmacology, there are inadequate treatment options for many psychiatric disorders, including major depressive disorder, bipolar disorder, schizophrenia, and anxiety disorders. This review explores emerging neurobiological targets beyond conventional monoaminergic approaches, focusing on sodium channels, Neuropeptide Y (NPY), Neurokinin 1 (NK1) receptors, P2 × 7 purinergic receptors, Sigma-1 receptors, and Orexin. Recent evidence suggests that sodium channel modulators, such as evenamide, may offer therapeutic benefits for treatment-resistant schizophrenia by stabilizing glutamatergic neurotransmission. NPY-based therapies have potential in stress-related disorders, foreshadowing rapid anxiolytic and antidepressant effects through modulation of the stress response. NK1 receptor antagonists, although inconsistent in mood disorders, show promise in addiction treatment by reducing substance cravings. The P2 × 7 receptor, a key regulator of neuroinflammation, has been implicated in mood disorders, and its pharmacological inhibition may provide neuroprotective benefits. Additionally, Sigma-1 receptor agonists, including Blarcamesine and Pridopidine, have shown neuroprotective and cognitive-enhancing properties, making them attractive candidates for psychiatric and neurodegenerative disorders. Orexin receptor antagonists, such as suvorexant and seltorexant, have potential in mood disorders and substance dependence, highlighting the broader therapeutic applications of targeting the orexinergic system. While these emerging therapeutic targets hold promise, challenges remain in translating preclinical findings into effective clinical applications. Large-scale, placebo-controlled trials are necessary to establish their efficacy and safety. The identification of biomarkers for patient stratification will be critical in the hitherto elusive goal of developing precision medicine approaches. Targeted pharmacological interventions offer a path toward more effective, well-tolerated, and potentially individualized treatment options for patients with severe mental illness.

01 Jan 2026·Therapeutic Advances in Psychopharmacology

Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychotics: recent clinical findings from randomized trials

Article

Author: Roy, Arjun ; Hartman, Richard ; Sansi, Francesca ; Turolla, Alessio ; Chinellato, Giovanni ; Anand, Ravi

Background::

Despite their efficacy in improving positive symptoms, first- and second-generation antipsychotics (FGAs and SGAs) fail to provide benefit to a large portion of patients with schizophrenia. Evenamide, uniquely acting at the site of dysfunction, normalizes hippocampal glutamatergic aberrant activity and reduces downstream hyperdopaminergic state, potentially alleviating also negative and cognitive symptoms, and providing benefit to patients with treatment-resistant schizophrenia (TRS) or inadequate response to antipsychotics (APs).

Objectives::

Evaluate the clinical benefits of glutamate modulation through evenamide as an add-on treatment to FGAs and SGAs in patients with TRS or inadequate response to APs.

Design::

Post-hoc analyses of results from two phase II/III clinical trials with evenamide add-on to antipsychotic treatment.

Methods::

Data from Study 014/015, an open-label, 1-year trial in patients with TRS, was analyzed to assess the proportion of patients no longer meeting the baseline severity criteria for TRS (modified Intent-to-Treat (mITT) population; Observed Cases (OC)) and the proportion of patients in the mITT population achieving remission. Data from Study 008A, a randomized, double-blind, placebo-controlled, 4-week trial in patients with schizophrenia not adequately benefiting from SGA (including clozapine), was analyzed to assess patients’ response according to the number of previously failed AP attempts (ITT population; mixed model repeated measures (MMRM) linear regression model). The effect of evenamide on social functioning and life engagement was evaluated in both studies (mITT population) using an MMRM linear regression model for Study 008A and an OC analysis for Study 014/015.

Results::

Patients with TRS receiving evenamide add-on for 1-year improved to such an extent that 55% of them no longer satisfied baseline TRS severity criteria, and approximately one-fourth achieved remission according to literature criteria (27.6% Lieberman et al., 1993; 25.0% Andreasen et al., 2005). In Study 008A, irrespective of the number of failed APs, a statistically significant drug-placebo difference was observed in patients with a single failed attempt (−4.9, p = 0.0122) and in those with 2 or more failed attempts (−2.36, p = 0.0311). Moreover, add-on treatment with evenamide in Study 014/015 was associated with a progressive improvement on the PANSS subdomains of social functioning and life engagement. In Study 008A as well, evenamide resulted in a greater effect, compared to placebo, on the same subdomains.

Conclusion::

Add-on treatment with evenamide to APs (including clozapine) was associated with clinically meaningful and progressive long-term benefits across numerous post-hoc analyses including improvements on patient’s daily life and functioning.

01 Oct 2025·NEUROPSYCHOPHARMACOLOGY

Evenamide reverses schizophrenia-related dysfunction in a neurodevelopmental animal model

Article

Author: Rachel A. Walsh ; Anthony A. Grace ; Daniela L. Uliana ; Debora Fabris

Schizophrenia is characterized by positive, negative, and cognitive symptoms. However, current D2-based antipsychotic drugs only address primarily positive symptoms. Limbic hippocampus hyperexcitability is a key pathological state of schizophrenia, representing an ideal therapeutic target. Evenamide is a selective voltage-gated sodium channel blocker that reduces neuronal hyperexcitability. We examined the effect of acute evenamide treatment on the hyperdopaminergic state, hippocampal hyperexcitability, social deficits, and recognition memory in the methylazoxymethanol acetate (MAM) neurodevelopmental model. Male and female Sprague-Dawley offspring from dams treated with saline or MAM on gestational day 17 were tested as adults (postnatal day >65). Electrophysiological recordings were made in the ventral tegmental area (VTA) and ventral hippocampus (vHipp) and social approach and novel object recognition were tested. Evenamide (3 mg/kg i.p.) normalized the number of spontaneously active DA neurons in the VTA of female and male MAM rats and reduced pyramidal neuron hyperactivity in the vHipp. The hyperdopaminergic state in the VTA of female and male MAM rats was also rescued by local evenamide injection in the vHipp (1 µM). Systemic evenamide also reversed the recognition memory impairment of female and male MAM rats. For social deficits, only male MAM rats exhibit a reduced social sniffing time that was normalized by evenamide. These findings suggest that evenamide's efficacy in downregulating the hyperdopaminergic state, social deficits, and recognition memory impairment may result from its ability to attenuate vHipp hyperexcitability. Therefore, evenamide could offer a novel therapeutic strategy that is capable of addressing positive, cognitive, and negative symptoms of schizophrenia.

News (Medical) associated with Evenamide Hydrochloride

02 Jul 2026

·www.businesswire.com

Newron Provides Update Following Type A Meeting With the FDA

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it had a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the hold on the enrollment of new patients at US sites of its Phase III ENIGMA-TRS 2 study of evenamide, as reported on April 29, 2026. Evenamide targets the modulation of excessive release of glutamate in patients suffering from treatment-resistant schizophrenia (TRS). Evenamide targets the modulation of excessive release of glutamate in patients suffering from treatment-resistant schizophrenia (TRS). The face-to-face meeting was constructive and the parties discussed potential actions towards the resolution of issues that led to the hold. Newron, as agreed with the agency, plans to propose changes to address the agency’s concerns. The Company is very thankful to the FDA for the opportunity to discuss and help expedite discussions leading to the resolution of the issues in the near future. About ENIGMA-TRS ENIGMA-TRS 1 is an ongoing, international, 52-week, randomized, double-blind, placebo-controlled Phase III study evaluating the efficacy, tolerability, and safety of the 15mg BID and 30mg BID therapeutic doses of evenamide compared to placebo. Patients on second-generation antipsychotics, including clozapine, will meet Treatment Response and Resistance Psychosis international consensus criteria for TRS. The study will enroll at least 600 patients at study centers in Europe, Asia, Latin America, and Canada. The first patients were successfully enrolled in August 2025, following the completion of a rigorous 42-day screening period. Patients are currently being enrolled across 15 countries on all target continents. The primary assessment of efficacy and safety of ENIGMA-TRS 1 will be performed 12 weeks after randomization to treatment. Following this initial period, the study will continue double-blind and placebo-controlled until the 26- and 52-week time points. The primary efficacy endpoint of the trial will be the change from baseline in the Positive and Negative Syndrome Scale (PANSS) scores at 12 weeks. Newron expects to announce results from the 12-week primary endpoint assessment in QIV 2026. ENIGMA-TRS 2 is taking place at centers in the US and selected additional countries with the same screening procedure as the ENIGMA-TRS 1 trial. ENIGMA-TRS 2 will include at least 400 patients in a 12-week, randomized, double-blind, placebo-controlled Phase III study, designed to evaluate the efficacy, tolerability, and safety of the 15mg BID dose of evenamide compared to placebo. In December 2025, ENIGMA-TRS 2 was initiated in the US, following approvals from the US Food and Drug Administration (FDA) and the Institutional Review Board (IRB). The efficacy and safety analysis will be performed at the 12-week point following successful completion of the study. About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of innovative therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso near Milan, Italy, the Company has a strong track record of advancing neuroscience-based treatments from discovery to market. Newron’s lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently developed in the global pivotal ENIGMA-TRS Phase III development program. Clinical trial results to date demonstrate the benefits of this drug candidate in the TRS as well as poorly responding patient population, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron’s first marketed product, Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea. The product is commercialized by Newron’s partner Zambon, with Supernus Pharmaceuticals holding marketing rights in the U.S., and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories. For more information, please visit: https://www.newron.com and connect with us on LinkedIn. Important Notices This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

Phase 3Drug ApprovalPhase 2

02 Jul 2026

·www.newron.com

Newron provides update following Type A meeting with the FDA

Ad hoc announcement pursuant to Art. 53 LR Parties discussed information provided by Newron and changes needed by FDA to consider re-start of enrollment in ENIGMA-TRS 2 study in the US Milan, Italy, and Morristown, NJ, USA – July 2, 2026, 05:45 pm CEST – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced that it had a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the hold on the enrollment of new patients at US sites of its Phase III ENIGMA-TRS 2 study of evenamide, as reported on April 29, 2026. Evenamide targets the modulation of excessive release of glutamate in patients suffering from treatment-resistant schizophrenia (TRS). The face-to-face meeting was constructive and the parties discussed potential actions towards the resolution of issues that led to the hold. Newron, as agreed with the agency, plans to propose changes to address the agency’s concerns. The Company is very thankful to the FDA for the opportunity to discuss and help expedite discussions leading to the resolution of the issues in the near future. ENIGMA-TRS 1 is an ongoing, international, 52-week, randomized, double-blind, placebo-controlled Phase III study evaluating the efficacy, tolerability, and safety of the 15mg BID and 30mg BID therapeutic doses of evenamide compared to placebo. Patients on second-generation antipsychotics, including clozapine, will meet Treatment Response and Resistance Psychosis international consensus criteria for TRS. The study will enroll at least 600 patients at study centers in Europe, Asia, Latin America, and Canada. The first patients were successfully enrolled in August 2025, following the completion of a rigorous 42-day screening period. Patients are currently being enrolled across 15 countries on all target continents. The primary assessment of efficacy and safety of ENIGMA-TRS 1 will be performed 12 weeks after randomization to treatment. Following this initial period, the study will continue double-blind and placebo-controlled until the 26- and 52-week time points. The primary efficacy endpoint of the trial will be the change from baseline in the Positive and Negative Syndrome Scale (PANSS) scores at 12 weeks. Newron expects to announce results from the 12-week primary endpoint assessment in QIV 2026. ENIGMA-TRS 2 is taking place at centers in the US and selected additional countries with the same screening procedure as the ENIGMA-TRS 1 trial. ENIGMA-TRS 2 will include at least 400 patients in a 12-week, randomized, double-blind, placebo-controlled Phase III study, designed to evaluate the efficacy, tolerability, and safety of the 15mg BID dose of evenamide compared to placebo. In December 2025, ENIGMA-TRS 2 was initiated in the US, following approvals from the US Food and Drug Administration (FDA) and the Institutional Review Board (IRB). The efficacy and safety analysis will be performed at the 12-week point following successful completion of the study. About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of innovative therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso near Milan, Italy, the Company has a strong track record of advancing neuroscience-based treatments from discovery to market. Newron’s lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently developed in the global pivotal ENIGMA-TRS Phase III development program. Clinical trial results to date demonstrate the benefits of this drug candidate in the TRS as well as poorly responding patient population, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron’s first marketed product, Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea. The product is commercialized by Newron’s partner Zambon, with Supernus Pharmaceuticals holding marketing rights in the U.S., and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories. For more information, please visit: https://www.newron.com and connect with us on LinkedIn. For more information, please contact: Newron Stefan Weber – CEO; +39 02 6103 46 26, pr@newron.com UK/Europe Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting; +44 20 3727 1000, SCnewron@fticonsulting.com Switzerland Valentin Handschin, IRF; +41 43 244 81 54, handschin@irf-reputation.ch Germany/Europe Anne Hennecke / Maximilian Schur, MC Services; +49 211 52925227, newron@mc-services.eu USA Casey Darby, LaVoieHealthScience; +1 617 351 0244, cdarby@lavoiehealthscience.com Important Notices This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

Phase 3Drug Approval

28 May 2026

·www.businesswire.com

Newron Pharmaceuticals to Participate in June Investor Conferences

Phase 3Drug ApprovalLicense out/in

100 Deals associated with Evenamide Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Evenamide Hydrochloride	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Schizophrenia, Treatment-Resistant	Phase 3	Argentina	Newron Pharmaceuticals SpA	16 Dec 2025
Schizophrenia, Treatment-Resistant	Phase 3	Brazil	Newron Pharmaceuticals SpA	16 Dec 2025
Schizophrenia, Treatment-Resistant	Phase 3	Bulgaria	Newron Pharmaceuticals SpA	16 Dec 2025
Schizophrenia, Treatment-Resistant	Phase 3	Canada	Newron Pharmaceuticals SpA	16 Dec 2025
Schizophrenia, Treatment-Resistant	Phase 3	Colombia	Newron Pharmaceuticals SpA	16 Dec 2025
Schizophrenia, Treatment-Resistant	Phase 3	Croatia	Newron Pharmaceuticals SpA	16 Dec 2025
Schizophrenia, Treatment-Resistant	Phase 3	Czechia	Newron Pharmaceuticals SpA	16 Dec 2025
Schizophrenia, Treatment-Resistant	Phase 3	France	Newron Pharmaceuticals SpA	16 Dec 2025
Schizophrenia, Treatment-Resistant	Phase 3	Germany	Newron Pharmaceuticals SpA	16 Dec 2025
Schizophrenia, Treatment-Resistant	Phase 3	Hungary	Newron Pharmaceuticals SpA	16 Dec 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EUCTR2020-006062-36-CZ (008A, Pubmed \| NEWS 1 \| NEWS 2)	Phase 2/3	Schizophrenia	291	Evenamide	dlgmkrakcb(kizypfvvjy) = bcdvkuxibw nxhuteumud (wleszlprmj ) View more	Positive	30 Apr 2024
EUCTR2020-006062-36-CZ (008A, Pubmed \| NEWS 1 \| NEWS 2)	Phase 2/3	Schizophrenia	291	安慰剂	dlgmkrakcb(kizypfvvjy) = dcvsptyyqz nxhuteumud (wleszlprmj ) View more	Positive	30 Apr 2024
EUCTR2020-000437-41-IT (Study 015, Biospace) Manual	Not Applicable	Schizophrenia, Treatment-Resistant	121	Evenamide	jqliukfaaf(aapzsvddgd) = jfeoexzmkt rxryrfiwoh (iiuyuqllqr ) View more	Positive	04 Jan 2024
Study 015 (Corporate Publications) Manual	Phase 2	Schizophrenia, Treatment-Resistant	97	Evenamide	uhqfmhaepn(alqeztnfqa) = owvupoeeqf ozvllffkiw (obwrspihib ) View more	Positive	07 May 2023
CTRI/2020/09/027537 (Corporate Publications) Manual	Phase 2	Schizophrenia, Treatment-Resistant	161	Evenamide	lyhcaiubmk(lsoioyfbfl) = The mean Positive and Negative Syndrome Scale (PANSS) total score, Clinical Global Impression of Severity (CGI-S) rating, and the Strauss-Carpenter Level of Functioning (LOF) total score significantly improved compared to baseline (p<0.001). rotzypeqec (pkcrmhozms ) View more	Positive	20 Mar 2023
CTRI/2020/09/027537 (Corporate Publications) Manual	Phase 2	Schizophrenia, Treatment-Resistant	100	evenamide	rweyeusqhp(wpcczrejzo) = The proportion of patients experiencing clinically meaningful improvement (i.e., patients rated at least “much improved”) on the Clinical Global Impression of Change (CGI-C) increased by an additional 10% at one year from the proportion at week six (27%). oueoucdgba (rwgwfcecdb ) View more	Positive	16 Feb 2023
Corporate Publications Manual	Not Applicable	Schizophrenia, Treatment-Resistant	100	evenamide	clenfipcut(uqnepsscec) = dintgtbdqa lpnzjxnvmb (mqcctoqkum ) View more	Positive	07 Jun 2022
NCT01955564 (CTgov)	Phase 1	Schizophrenia	54	NW-3509a (Cohort 1)	jxrthtbxqc = xxxhqjnsxn uvkjctltax (xpduibvggk, byqnowicjx - zbggjceaij) View more	-	20 Jun 2017
NCT01955564 (CTgov)	Phase 1	Schizophrenia	54	NW-3509a (Cohort 2)	jxrthtbxqc = vfrirghrji uvkjctltax (xpduibvggk, ikjssicmaa - kfcumndkkf) View more	-	20 Jun 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis